Off-label drug use is neither inherently unethical nor automatically justified—it depends entirely on whether the prescriber has sound scientific evidence and sound medical reasoning to support the decision. A doctor prescribing a blood pressure medication (propranolol) to a dementia patient to manage agitation, even though the drug is not FDA-approved for that use, is engaging in off-label prescribing that may be medically reasonable if evidence supports it. Yet off-label use without robust evidence—such as prescribing an antidepressant for anxiety when better alternatives exist—raises legitimate ethical concerns about patient safety and informed consent. Off-label prescribing is legal in the United States.
The FDA approves medications for specific uses, but once a drug is approved, physicians have the legal authority to prescribe it for any indication they believe is medically appropriate. The key ethical constraint is not whether prescribing off-label is permitted, but whether it is justified by evidence and informed by the patient’s specific clinical circumstances. The prevalence of off-label prescribing reflects both the reality of modern medicine and a significant gap in our understanding of drug safety across diverse patient populations. Between 20 and 25 percent of all prescriptions written in the United States are off-label—meaning they are for conditions, patient populations, or dosages not specifically approved by the FDA. In some therapeutic areas, the rates are far higher: more than half of all cancer medications are used off-label, and 67.58 percent of drugs given in neonatal intensive care units are off-label.
Table of Contents
- How Common Is Off-Label Prescribing in Dementia and Brain Health Care?
- What Are the Safety Risks of Off-Label Drug Use?
- Who Is Most Vulnerable to Off-Label Drug Prescribing?
- What Should Patients and Families Know Before Taking Off-Label Medications?
- Why Do High Volumes of Off-Label Prescribing Lack Adequate Evidence?
- How Does the Law Regulate Off-Label Drug Use Versus Off-Label Marketing?
- Off-Label Use in Urgent Clinical Situations and Pediatric Emergency Care
How Common Is Off-Label Prescribing in Dementia and Brain Health Care?
Off-label prescribing is standard practice in treating dementia and cognitive decline, where FDA-approved medications are limited and clinical situations are highly individualized. For behavioral and psychological symptoms of dementia—agitation, depression, sleep disturbances, and anxiety—doctors regularly prescribe antipsychotics (like aripiprazole or quetiapine) off-label, antidepressants off-label, and sedatives off-label. Psychiatric medications account for 31 percent of all off-label prescriptions across medicine, and rates in dementia populations are likely much higher. The historical trend shows off-label use has grown significantly.
In 1993, 30.2 percent of prescriptions were off-label; by 2008, that figure had risen to 39.1 percent, though recent data suggests the rate stabilized around 20-25 percent as awareness of safety issues increased. In elderly patients with dementia—who were historically excluded from most clinical drug trials—off-label use is often unavoidable because FDA-approved alternatives may be inadequate or contraindicated. The problem is that while off-label prescribing for dementia may sometimes be necessary, it frequently occurs without adequate evidence. High volumes of antipsychotics, antidepressants, and sedatives are prescribed off-label to dementia patients for behavioral symptoms, yet controlled trials supporting these uses are often weak or absent. This creates an ethical tension: the practice is legal and sometimes clinically necessary, yet many individual prescribing decisions lack the sound scientific foundation that ethics require.
What Are the Safety Risks of Off-Label Drug Use?
The safety signal is clear and troubling: off-label use is associated with significantly higher rates of adverse events. Adults receiving off-label medications experience adverse effects at a rate 44 percent higher than those receiving on-label medications. In children, the relative risk of adverse events from off-label prescribing is as high as 3.4 compared to on-label use—meaning a child receiving an off-label medication faces more than three times the risk of harm. In dementia populations specifically, the risks are compounded because elderly patients often take multiple medications simultaneously (polypharmacy), have altered metabolism due to age and disease, and may not be able to clearly report side effects.
An antipsychotic prescribed off-label for agitation in an Alzheimer’s disease patient carries risks of stroke, sedation, falls, and cognitive decline—risks that were not rigorously studied in that population before the medication was approved for other uses. A sedative prescribed off-label for sleep disturbances may increase confusion, paradoxically worsening behavioral symptoms. Off-label use is also associated with worse overall health outcomes and increased healthcare utilization, according to population health studies. This means patients receiving off-label medications not only face higher individual risk of adverse events, but also end up using healthcare resources more intensively—more hospital visits, more emergency department trips, higher costs—which itself reflects inadequate treatment or harm being managed reactively rather than prevented.
Who Is Most Vulnerable to Off-Label Drug Prescribing?
Certain populations bear a disproportionate burden of off-label drug use precisely because they were excluded from clinical trials when medications were being developed and tested. Elderly patients, including those with dementia, were historically underrepresented in drug trials. Mentally ill individuals, pregnant and lactating women, and children were similarly excluded. The result is that once a drug is approved based on trial data from younger, healthier, less diverse populations, it is then used off-label in the very groups for which we have the least evidence. Pediatric patients are the most dramatic example of this gap. Fifty-six percent of pediatric prescriptions are off-label or unlicensed.
In neonatal intensive care units, 67.58 percent of all drug use is off-label or unlicensed, and 93.44 percent of neonates receive at least one off-label drug during their stay. Yet neonates have vastly different drug metabolism, kidney function, and susceptibility to adverse effects than adults. The fact that infants receive mostly unmeasured and unstudied medications illustrates how pervasive the ethical problem is. Dementia patients occupy a similar vulnerable position to pediatric patients. They are often unable to give truly informed consent, may not reliably report side effects, and frequently have complex medical conditions that complicate interpretation of whether a drug is working or causing harm. When a memory care facility gives an antipsychotic off-label to a patient with severe dementia for behavioral management, the patient cannot advocate for safer alternatives, making the ethical obligation on the prescriber’s shoulders that much heavier.
What Should Patients and Families Know Before Taking Off-Label Medications?
If a doctor recommends an off-label medication for dementia or brain health, the first question to ask is: What evidence supports this use? Sound medical reasoning does not mean “the doctor thinks it might help.” It means the prescriber can point to published studies, clinical experience in similar patient populations, or established clinical guidelines that indicate the medication has been used for this indication with measurable benefit. A responsible prescriber will explain whether the recommendation is based on strong evidence (such as randomized controlled trials), weaker evidence (such as case reports or clinical experience), or genuine uncertainty with honest acknowledgment of that uncertainty. The trade-off between benefit and risk becomes more important when evidence is limited. An antipsychotic prescribed off-label for agitation in dementia may indeed reduce agitation, but it carries risks of stroke, metabolic effects, and cognitive decline.
The ethical prescriber discusses this trade-off explicitly: “This medication may help with agitation, but here are the specific risks we’re monitoring for.” Patients and families should insist on this conversation and should be comfortable asking for a second opinion if a doctor is vague about the evidence or dismissive of concerns about off-label use. Insurance coverage also affects off-label prescribing. Some insurance formularies are more restrictive for on-label uses but less restrictive for off-label uses, creating a perverse incentive for doctors to prescribe off-label simply because it’s easier to get approved. Families should ask whether the recommended medication is on-label or off-label and, if off-label, whether cost or insurance formulary restrictions are driving the recommendation rather than medical evidence.
Why Do High Volumes of Off-Label Prescribing Lack Adequate Evidence?
The reality of clinical practice is that doctors often prescribe off-label because FDA-approved alternatives are limited, inadequate, or unavailable. In dementia care, there are very few FDA-approved medications specifically for behavioral symptoms. Antipsychotics are approved for psychotic symptoms in schizophrenia, not for agitation in dementia. Antidepressants are approved for major depression, not for generalized anxiety in a dementia patient. Rather than leave a suffering patient untreated, doctors reach for off-label options. This is understandable, but it is not the same as having sound evidence that these off-label uses are safe or effective. The darker reality is that some off-label prescribing occurs for reasons that have nothing to do with patient benefit.
Pharmaceutical companies cannot legally market drugs for off-label uses, but they can (and historically did) promote medications to doctors through sales representatives, continuing medical education, and other channels that encourage off-label prescribing without requiring rigorous evidence. Insurance formularies sometimes favor off-label uses. Habit and inertia play a role: if a doctor has used an antipsychotic off-label for dementia patients for twenty years, they may continue doing so without questioning whether current evidence supports it. A significant proportion of psychiatric medication prescriptions—antidepressants, antipsychotics, anxiolytics, and sedatives—are written off-label without high-quality evidence supporting the indication. This has been documented repeatedly in research literature. It is not that individual doctors are unethical; it is that the system permits large-scale prescribing without adequate evidence, and economic incentives often favor off-label use. The ethical burden falls on individual prescribers, patients, and families to ask hard questions about evidence.
How Does the Law Regulate Off-Label Drug Use Versus Off-Label Marketing?
The legal distinction is crucial. Off-label prescribing by a physician is legal. Off-label marketing by a pharmaceutical company is illegal and carries significant penalties. Once the FDA approves a drug, doctors can prescribe it for any medically appropriate use; the law trusts physician judgment and the doctor-patient relationship.
But the company that manufactures the drug cannot advertise it, promote it, or market it for unapproved uses—that would constitute illegal marketing of an unapproved drug. This legal framework recognizes a core principle: physicians are trained to use medical judgment, and the individual doctor-patient relationship can accommodate off-label use in ways that public marketing cannot. Yet the framework also has a weakness: it assumes physicians have adequate access to evidence about off-label uses, which is often not true. A doctor might reasonably prescribe a sedative off-label for a dementia patient’s sleep disturbance based on limited information, without access to high-quality comparative studies showing whether that sedative is more effective or safer than alternatives.
Off-Label Use in Urgent Clinical Situations and Pediatric Emergency Care
In emergency and urgent situations, off-label prescribing is sometimes ethically defensible even with limited evidence. A child in pediatric emergency care may need a medication for a life-threatening condition when no FDA-approved alternative exists and delaying treatment is dangerous. A dementia patient in acute delirium may need sedation off-label when the licensed options are insufficient. These situations present a genuine ethical permission: when the benefit of treating the emergency justifies the risk of off-label use, physicians reasonably may proceed without waiting for perfect evidence.
However, even in emergencies, the ethical baseline is sound reasoning and informed consent where possible. A pediatric emergency physician prescribing a medication off-label for an acute condition should be able to explain why, in that emergency, the off-label use is reasonable. When the same patient leaves the emergency department and continues on that off-label medication chronically—not because of ongoing emergency need but because it became habitual—the ethical justification evaporates. Research published in late 2025 in pediatric emergency care literature has renewed attention to this distinction, arguing that ethical and clinical oversight of off-label use must be stronger in chronic settings than in true emergencies.
- —
